Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: BMS names new CEO; Novartis culls pipeline; AstraZeneca taps Chinese innovation; Q2 approvals to look out for; and a look at deal-making trends in 2022.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 28 April 2023, including: Bristol Myers Squibb Company names new CEO; Novartis AG culls pipeline; AstraZeneca PLC taps Chinese innovation; Q2 approvals to look out for; and a look at deal-making trends in 2022.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Bristol’s Boerner To Succeed CEO Caforio With Launch Execution In The Spotlight" - Scrip, 26 Apr, 2023.)
(Also see "Novartis Culls Pipeline As ‘Pure-Play’ Drive Progresses" - Scrip, 25 Apr, 2023.)
(Also see "AstraZeneca Oncology R&D Head On China Biotech Innovation" - Scrip, 20 Apr, 2023.)
(Also see "10 Approvals To Look Out For In Q2" - Scrip, 20 Apr, 2023.)
(Also see "2022 Deal-Making Snapshot: One Big Deal Didn’t Change The Downward Trends" - Scrip, 21 Apr, 2023.)